Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

Hormonal Regulation

Hormonal Regulation

Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.

Target Cell Response to Hormones

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...

Hormonal Control of the Ovarian Cycle

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Prostate·2026

Same author

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Annals of nuclear medicine·2026

Same author

Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men.

International journal of urology : official journal of the Japanese Urological Association·2026

Same author

Prostate-Specific Membrane Antigen Positron Emission Tomography in Japan: An Implementation Gap in the Era of Global Adoption.

Asia-Pacific journal of clinical oncology·2026

Same author

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

International journal of urology : official journal of the Japanese Urological Association·2026

Same author

Fibroblast-mediated KRAS activation in double-negative prostate cancer.

Cell death & disease·2026

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Hormonal therapy.

Mikio Namiki¹, Satoru Ueno, Yasuhide Kitagawa

¹Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan. namiki1@kenroku.kanazawa-u.ac.jp

International Journal of Clinical Oncology

|December 12, 2007

Summary

Primary androgen deprivation therapy (PADT) is often used for localized prostate cancer in Japan despite guidelines. This review examines PADT efficacy, patient selection, and treatment duration, suggesting it can control over 30% of low-risk cases long-term.

Related Experiment Videos

Last Updated: Jul 9, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

Oncology
Urology

Background:

Clinical guidelines, like the NCI-PDQ, do not recommend primary androgen deprivation therapy (PADT) for localized prostate cancer.
PADT is frequently used in Japan due to patient preference for less invasive treatments and physician experience.

Purpose of the Study:

To review clinical trials demonstrating the efficacy of PADT for localized and locally advanced prostate cancer.
To identify patient candidates for PADT and discuss optimal treatment duration.
To propose treatment algorithms for localized prostate cancer, including high-risk groups.

Main Methods:

Review of clinical trials on PADT efficacy for prostate cancer.
Analysis of patient selection criteria for PADT.
Discussion of PADT duration and potential for cancer progression.

Main Results:

PADT can achieve long-term control in over 30% of low- or intermediate-risk localized prostate cancer cases.
Short-term or intermittent PADT is not recommended due to the risk of promoting more malignant cancer cells.
Adverse effects of androgen deprivation therapy (ADT) require adequate management.

Conclusions:

PADT can be effective for selected localized prostate cancer patients, particularly in low- and intermediate-risk groups.
Continuous, long-term PADT is preferred over intermittent or short-term regimens.
Management of ADT side effects and development of targeted therapies are crucial for improving patient outcomes.